Ratings Nanobiotix

Equities

NANO

FR0011341205

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-04-26 am EDT			5-day change	1st Jan Change
5.45 ^EUR	+0.93%		+3.81%	-17.92%

Apr. 25	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
NANOBIOTIX	-17.92%	274M	-
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
MODERNA, INC.	+8.57%	41.34B	B-
LONZA GROUP AG	+49.22%	41.61B	A
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes